Connie L. Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Connie L. Chen has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
Nicola Powles-Glover
Knoell Consulting Ltd., 22 Cathedral Road, Cardiff CF11 9LJ, United Kingdom
4 shared publicationsRonald L. Wange
US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD 20993, USA
4 shared publicationsAmer Jamalpoor
Toxys, Leiden Bioscience Park, Oegstgeest, the Netherlands
3 shared publicationsBelen Tornesi
Medicines for Malaria Venture (MMV) Geneva Switzerland
3 shared publicationsFrancesco Marchetti
Environmental Health Science and Research Bureau, Health Canada Ottawa Canada
3 shared publications- Lucilia Pereira Mouriès
Health and Environmental Sciences Institute (HESI), Washington, DC, USA
3 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in Cytotherapy
Key Considerations for In Vitro Assessment of On- and Off-target/ Off-Disease Effects of Chimeric Antigen Receptor T-Cell Therapies
- 27 October 2026
- Published by Elsevier in Cytotherapy
Open AccessKey Considerations for In Vitro Assessment of On- and Off-target/ Off-Disease Effects of Chimeric Antigen Receptor T-Cell Therapies
- Open Access
- 29 July 2026
- Published by Springer Nature in Gene Therapy
- p. 1-11
SACF and GILA for in vitro transformation assessment of CRISPR/Cas9-edited cell therapy candidates: a multi-site study
Tumorigenicity is a key safety concern for CRISPR/Cas9-based gene therapies, yet its assessment remains challenging due to the lack of relevant and sensitive in vivo models. This HESI Global multi-site study evaluated the Soft Agar Colony Formation (SACF) assay and the Growth in Low Attachment (GILA) assay for in vitro transformation testing of CRISPR/Cas9-edited cells as part of tumorigenicity risk assessment. Across four laboratories, MCF10A cells were spiked with varying concentrations of cells carrying a CRISPR/Cas9-mediated knockout of the known tumor suppressor PTPN12 to determine the assays’ limit of detection (LOD), robustness and reproducibility. Both assays demonstrated a consistent LOD of 0.8% at most sites, with SACF showing a broader dynamic range and slightly stronger correlation across laboratories. GILA exhibited weaker correlation due to plateauing at high spike-in concentrations (>12.5%), and excluding these conditions improved inter-laboratory correlations. Additionally, the study identified key determinants of assay success, including the selection of appropriate cell lines and lots, and ensuring sufficient recovery time post-thaw. Together, these data establish multi-site reproducibility of SACF and GILA in the MCF10A-PTPN12 model evaluated here and support their use as animal-free, development-stage characterization tools contributing to tumorigenicity evidence generation.
- 29 July 2026
- Published by Springer Nature in Gene Therapy
- p. 1-11
Open AccessSACF and GILA for in vitro transformation assessment of CRISPR/Cas9-edited cell therapy candidates: a multi-site study
Tumorigenicity is a key safety concern for CRISPR/Cas9-based gene therapies, yet its assessment remains challenging due to the lack of relevant and sensitive in vivo models. This HESI Global multi-site study evaluated the Soft Agar Colony Formation (SACF) assay and the Growth in Low Attachment (GILA) assay for in vitro transformation testing of CRISPR/Cas9-edited cells as part of tumorigenicity risk assessment. Across four laboratories, MCF10A cells were spiked with varying concentrations of cells carrying a CRISPR/Cas9-mediated knockout of the known tumor suppressor PTPN12 to determine the assays’ limit of detection (LOD), robustness and reproducibility. Both assays demonstrated a consistent LOD of 0.8% at most sites, with SACF showing a broader dynamic range and slightly stronger correlation across laboratories. GILA exhibited weaker correlation due to plateauing at high spike-in concentrations (>12.5%), and excluding these conditions improved inter-laboratory correlations. Additionally, the study identified key determinants of assay success, including the selection of appropriate cell lines and lots, and ensuring sufficient recovery time post-thaw. Together, these data establish multi-site reproducibility of SACF and GILA in the MCF10A-PTPN12 model evaluated here and support their use as animal-free, development-stage characterization tools contributing to tumorigenicity evidence generation.
- Open Access
- 4 June 2026
- Published by Wiley in Birth Defects Research
- Vol. 118 (6) , e70074
Nonclinical Considerations for Support of Pregnancy and Lactation in Clinical Trials
Background: Pregnant and breastfeeding individuals remain underrepresented in clinical drug development, leaving health care providers and patients with limited data to inform treatment decisions. Current practice relies heavily on nonclinical developmental and reproductive toxicity (DART) studies in animals, while clinical trials typically exclude pregnant and breastfeeding populations or require highly effective contraception for women of childbearing potential. Consequently, medications may be used during pregnancy or lactation despite limited supporting evidence, which can lead to treatment interruption, suboptimal dosing, and increased maternal or fetal risk. Emerging regulatory guidance, including draft ICH Guideline on Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials (E21), highlights the ethical and clinical need to generate data directly in these populations. Methods: This paper evaluates the current regulatory framework for nonclinical studies described in ICH S5(R3) and M3(R2) and examines how these studies can support the enrollment of pregnant and breastfeeding individuals in clinical trials. It proposes pragmatic adaptations to align nonclinical testing with the anticipated clinical context of use and considers the role of new approach methodologies (NAMs) and alternative study designs. Results: Potential DART strategies are described that could enable the inclusion of pregnant individuals in clinical trials based on factors such as dosing duration, route of administration, and study type (e.g., pharmacokinetic studies). The paper also considers the use of NAMs, including physiologically based pharmacokinetic modeling and in vitro assays, as well as alternative study designs such as preliminary pre‐ and postnatal development or extended embryo–fetal development studies. Approaches to inform studies in breastfeeding populations, including milk–plasma ratio modeling and translation from nonclinical data, are also discussed. Conclusions: These approaches support a shift from routine exclusion toward proactive and ethical inclusion of pregnant and breastfeeding individuals in clinical research, helping address longstanding evidence gaps and improving therapeutic decision‐making.
- 4 June 2026
- Published by Wiley in Birth Defects Research
- Vol. 118 (6) , e70074
Open AccessNonclinical Considerations for Support of Pregnancy and Lactation in Clinical Trials
Background: Pregnant and breastfeeding individuals remain underrepresented in clinical drug development, leaving health care providers and patients with limited data to inform treatment decisions. Current practice relies heavily on nonclinical developmental and reproductive toxicity (DART) studies in animals, while clinical trials typically exclude pregnant and breastfeeding populations or require highly effective contraception for women of childbearing potential. Consequently, medications may be used during pregnancy or lactation despite limited supporting evidence, which can lead to treatment interruption, suboptimal dosing, and increased maternal or fetal risk. Emerging regulatory guidance, including draft ICH Guideline on Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials (E21), highlights the ethical and clinical need to generate data directly in these populations. Methods: This paper evaluates the current regulatory framework for nonclinical studies described in ICH S5(R3) and M3(R2) and examines how these studies can support the enrollment of pregnant and breastfeeding individuals in clinical trials. It proposes pragmatic adaptations to align nonclinical testing with the anticipated clinical context of use and considers the role of new approach methodologies (NAMs) and alternative study designs. Results: Potential DART strategies are described that could enable the inclusion of pregnant individuals in clinical trials based on factors such as dosing duration, route of administration, and study type (e.g., pharmacokinetic studies). The paper also considers the use of NAMs, including physiologically based pharmacokinetic modeling and in vitro assays, as well as alternative study designs such as preliminary pre‐ and postnatal development or extended embryo–fetal development studies. Approaches to inform studies in breastfeeding populations, including milk–plasma ratio modeling and translation from nonclinical data, are also discussed. Conclusions: These approaches support a shift from routine exclusion toward proactive and ethical inclusion of pregnant and breastfeeding individuals in clinical research, helping address longstanding evidence gaps and improving therapeutic decision‐making.
- Open Access
- 14 May 2026
- Published by Wiley in Birth Defects Research
- Vol. 118 (5) , e70058
Ontogeny of Placental FcRn Protein During Human and Animal Pregnancy to Inform Developmental Toxicity Testing
Introduction: Species differences exist in Fc domain‐containing molecule transfer/biodistribution to the embryo‐fetus during pregnancy. Placentation was reviewed and placental neonatal Fc receptor (FcRn) quantitation in the chorioallantoic placenta (CAP) and/or inverted yolk sac placenta (InvYSP) was investigated across species throughout gestation to further understand and inform developmental toxicity testing of Fc domain‐containing molecules. Methods: Quantitative mass spectrometry was used to quantify FcRn protein in CAP and/or InvYSP throughout gestation in mouse, rat, guinea pig, rabbit, and nonhuman primate (NHP). In human placental tissues, immunohistochemistry was used to localize FcRn distribution during each trimester. Results: FcRn protein was detected and concentration increased throughout gestation in mouse, rat, guinea pig, and rabbit; with InvYSP concentration markedly higher compared with CAP at all gestational ages. In contrast, NHP FcRn protein concentration in the CAP remained constant throughout gestation. In humans, during 1st trimester, FcRn occurred in decidua, maternal endothelium, and maternal and fetal macrophages. During 2nd trimester, fetal FcRn increased in syncytiotrophoblasts and fetal chorionic vessels. FcRn expression decreased in maternal endothelium near term. Conclusions: FcRn protein was detected throughout gestation (including organogenesis) in placental tissue of all animal species. Regardless of FcRn location, these data support that Fc domain‐containing molecules can access the embryo‐fetus throughout gestation in all species, with the extent of transfer likely depending on FcRn concentration and size of the placenta. This information on placental FcRn ontogeny will help improve study design and translation of nonclinical developmental toxicity data to human safety assessment of Fc domain‐containing molecules.
- 14 May 2026
- Published by Wiley in Birth Defects Research
- Vol. 118 (5) , e70058
Open AccessOntogeny of Placental FcRn Protein During Human and Animal Pregnancy to Inform Developmental Toxicity Testing
Introduction: Species differences exist in Fc domain‐containing molecule transfer/biodistribution to the embryo‐fetus during pregnancy. Placentation was reviewed and placental neonatal Fc receptor (FcRn) quantitation in the chorioallantoic placenta (CAP) and/or inverted yolk sac placenta (InvYSP) was investigated across species throughout gestation to further understand and inform developmental toxicity testing of Fc domain‐containing molecules. Methods: Quantitative mass spectrometry was used to quantify FcRn protein in CAP and/or InvYSP throughout gestation in mouse, rat, guinea pig, rabbit, and nonhuman primate (NHP). In human placental tissues, immunohistochemistry was used to localize FcRn distribution during each trimester. Results: FcRn protein was detected and concentration increased throughout gestation in mouse, rat, guinea pig, and rabbit; with InvYSP concentration markedly higher compared with CAP at all gestational ages. In contrast, NHP FcRn protein concentration in the CAP remained constant throughout gestation. In humans, during 1st trimester, FcRn occurred in decidua, maternal endothelium, and maternal and fetal macrophages. During 2nd trimester, fetal FcRn increased in syncytiotrophoblasts and fetal chorionic vessels. FcRn expression decreased in maternal endothelium near term. Conclusions: FcRn protein was detected throughout gestation (including organogenesis) in placental tissue of all animal species. Regardless of FcRn location, these data support that Fc domain‐containing molecules can access the embryo‐fetus throughout gestation in all species, with the extent of transfer likely depending on FcRn concentration and size of the placenta. This information on placental FcRn ontogeny will help improve study design and translation of nonclinical developmental toxicity data to human safety assessment of Fc domain‐containing molecules.
- Open Access
- 14 February 2026
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 41 (4) , 225-236
Nitrosamine Ames Data Review and Method Development: proceedings of a US FDA/HESI workshop
Detection of N-nitrosamines (NA) in pharmaceuticals became a point of interest due to the mutagenic and carcinogenic potential of some compounds of this class, and their identification as nitrosated forms of marketed drugs, otherwise known as NA Drug Substance-Related Impurities (NDSRIs). The Ames test is used to assess the mutagenic potential of drug impurities, including NAs. Concerns over the sensitivity of the Ames test, as recommended in Organization for Economic Co-operation and Development Test Guideline 471, in predicting the rodent carcinogenic potential of NAs has prompted optimization of several test parameters used for detecting the mutagenicity of NAs (e.g. methods used for metabolic activation and the selection of tester strains). In order to discuss optimal Ames test conditions for the evaluation of NAs, including NDSRIs, the Office of New Drugs in the US Food and Drug Administration’s Center for Drug Evaluation and Research and the Health and Environmental Sciences Institute’s Genetic Toxicology Technical Committee co-organized and co-sponsored a workshop entitled “Nitrosamines: Ames Data Review and Method Development Workshop”. The workshop featured five sessions addressing charge questions pertinent to the Ames test conditions and performance through the presentation of data and panel discussions. This report outlines the key takeaway points from the workshop.
- 14 February 2026
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 41 (4) , 225-236
Open AccessNitrosamine Ames Data Review and Method Development: proceedings of a US FDA/HESI workshop
Detection of N-nitrosamines (NA) in pharmaceuticals became a point of interest due to the mutagenic and carcinogenic potential of some compounds of this class, and their identification as nitrosated forms of marketed drugs, otherwise known as NA Drug Substance-Related Impurities (NDSRIs). The Ames test is used to assess the mutagenic potential of drug impurities, including NAs. Concerns over the sensitivity of the Ames test, as recommended in Organization for Economic Co-operation and Development Test Guideline 471, in predicting the rodent carcinogenic potential of NAs has prompted optimization of several test parameters used for detecting the mutagenicity of NAs (e.g. methods used for metabolic activation and the selection of tester strains). In order to discuss optimal Ames test conditions for the evaluation of NAs, including NDSRIs, the Office of New Drugs in the US Food and Drug Administration’s Center for Drug Evaluation and Research and the Health and Environmental Sciences Institute’s Genetic Toxicology Technical Committee co-organized and co-sponsored a workshop entitled “Nitrosamines: Ames Data Review and Method Development Workshop”. The workshop featured five sessions addressing charge questions pertinent to the Ames test conditions and performance through the presentation of data and panel discussions. This report outlines the key takeaway points from the workshop.
- Open Access
- 26 December 2025
- Published by Elsevier in Reproductive Toxicology
- Vol. 140, 109144
Corrigendum to “Hypothesis-driven approach to developmental toxicity assessment: Using mechanistic information to inform testing” [Reprod. Toxicol. 140 (2026) 109119]
- 26 December 2025
- Published by Elsevier in Reproductive Toxicology
- Vol. 140, 109144
Open AccessCorrigendum to “Hypothesis-driven approach to developmental toxicity assessment: Using mechanistic information to inform testing” [Reprod. Toxicol. 140 (2026) 109119]
- Open Access
- 29 November 2025
- Published by Elsevier in Reproductive Toxicology
- Vol. 140, 109119
Hypothesis-driven approach to developmental toxicity assessment: Using mechanistic information to inform testing
- 29 November 2025
- Published by Elsevier in Reproductive Toxicology
- Vol. 140, 109119
Open AccessHypothesis-driven approach to developmental toxicity assessment: Using mechanistic information to inform testing
- Open Access
- 29 August 2025
- Published by Elsevier in Reproductive Toxicology
- Vol. 137, 109035
New approach methodologies for assessing developmental toxicity of pharmaceuticals: Case examples and future directions
- 29 August 2025
- Published by Elsevier in Reproductive Toxicology
- Vol. 137, 109035
Open AccessNew approach methodologies for assessing developmental toxicity of pharmaceuticals: Case examples and future directions
- Open Access
- 18 July 2025
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 66 (8) , 412-424
Critical Evaluation of Methods for the Identification of Aneugens
The genotoxic potential of chemicals must be evaluated in regulatory safety assessment settings, including but not limited to, the development of new pharmaceuticals, industrial chemicals, food and cosmetic ingredients, and agrochemicals. Initial assessment of the chromosome‐damaging potential of chemicals is often conducted in mammalian cells using the micronucleus (MN) assay, a method capable of detecting both aneugenicity and clastogenicity. When differentiation between these modes of action (MOAs) is necessary, microscopy‐based analyses using fluorescent In Situ Hybridization (FISH) or CREST staining have traditionally been employed. More recently, semi‐automated in vitro new approach methods (NAMs), which leverage technologies like flow cytometry and high‐content imaging, have increasingly been used across sectors due to their higher throughput and faster turnaround times. A SWOT (strengths, weaknesses, opportunities, and threats) analysis was conducted to systematically evaluate the merits and limitations of widely used NAMs in industry, with a focus on the pharmaceutical sector. Data from cultured mammalian cells exposed to reference aneugens (colchicine, taxol, and AMG900) and DNA‐reactive clastogens (mitomycin C and methyl methanesulfonate) across methodologies are presented to illustrate the process of distinguishing aneugens from clastogens for the different techniques described herein. Collectively, these analyses highlight the capabilities of NAMs to distinguish aneugens from clastogens. The newer, high information content, semi‐automated approaches were considered preferable to traditional microscopy‐based FISH and CREST techniques as they provide insight into molecular mechanisms of aneugenicity and help optimize the design of future in vivo genotoxicity studies to facilitate deriving points of departure which may contribute to margin of exposure estimates.
- 18 July 2025
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 66 (8) , 412-424
Open AccessCritical Evaluation of Methods for the Identification of Aneugens
The genotoxic potential of chemicals must be evaluated in regulatory safety assessment settings, including but not limited to, the development of new pharmaceuticals, industrial chemicals, food and cosmetic ingredients, and agrochemicals. Initial assessment of the chromosome‐damaging potential of chemicals is often conducted in mammalian cells using the micronucleus (MN) assay, a method capable of detecting both aneugenicity and clastogenicity. When differentiation between these modes of action (MOAs) is necessary, microscopy‐based analyses using fluorescent In Situ Hybridization (FISH) or CREST staining have traditionally been employed. More recently, semi‐automated in vitro new approach methods (NAMs), which leverage technologies like flow cytometry and high‐content imaging, have increasingly been used across sectors due to their higher throughput and faster turnaround times. A SWOT (strengths, weaknesses, opportunities, and threats) analysis was conducted to systematically evaluate the merits and limitations of widely used NAMs in industry, with a focus on the pharmaceutical sector. Data from cultured mammalian cells exposed to reference aneugens (colchicine, taxol, and AMG900) and DNA‐reactive clastogens (mitomycin C and methyl methanesulfonate) across methodologies are presented to illustrate the process of distinguishing aneugens from clastogens for the different techniques described herein. Collectively, these analyses highlight the capabilities of NAMs to distinguish aneugens from clastogens. The newer, high information content, semi‐automated approaches were considered preferable to traditional microscopy‐based FISH and CREST techniques as they provide insight into molecular mechanisms of aneugenicity and help optimize the design of future in vivo genotoxicity studies to facilitate deriving points of departure which may contribute to margin of exposure estimates.
- Open Access
- 30 June 2025
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 66 (6-7) , 311-326
Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing
Duplex Sequencing (DS) is an ultra‐accurate, error‐corrected next generation sequencing (ecNGS) technology for mutation analysis. A working group (WG) within Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee is investigating the suitability of ecNGS for regulatory mutagenicity testing, using DS as a model. Initial steps to promote acceptance require demonstrating technical reproducibility across DS‐experienced and inexperienced laboratories and establishing the method's sensitivity relative to conventional tests. Thus, the WG conducted a ‘reconstruction experiment’ to evaluate the transferability, reproducibility, and sensitivity of DS. TwinStrand Biosciences first applied DS to establish mutation frequency (MF) in DNA samples extracted from the livers of an untreated Sprague Dawley rat, or rats treated with either 100 mg/kg/day benzo[a]pyrene (B[a]P) for ten days or 40 mg/kg/day N‐ethyl‐N‐nitrosourea (ENU) for three days. Using the measured MF in these original samples, mixtures were then constructed using the B[a]P‐ and ENU‐treated samples to create “MF standards” with target MFs 1.2‐, 1.5‐, and 2‐fold greater than the untreated control. Aliquots of these standards were distributed to seven laboratories in North America and Europe. DS libraries were prepared by each laboratory and TwinStrand. All eight laboratories met library preparation and assay performance metrics to yield high quality sequencing data with MF in the expected ‘MF standard’ range. The measured MF and mutation spectra were nearly identical across the laboratories and a 2‐fold increase in MF could readily be identified in all labs relative to the untreated controls. The results confirm the high reproducibility and sensitivity of DS for mutagenicity assessment.
- 30 June 2025
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 66 (6-7) , 311-326
Open AccessTransferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing
Duplex Sequencing (DS) is an ultra‐accurate, error‐corrected next generation sequencing (ecNGS) technology for mutation analysis. A working group (WG) within Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee is investigating the suitability of ecNGS for regulatory mutagenicity testing, using DS as a model. Initial steps to promote acceptance require demonstrating technical reproducibility across DS‐experienced and inexperienced laboratories and establishing the method's sensitivity relative to conventional tests. Thus, the WG conducted a ‘reconstruction experiment’ to evaluate the transferability, reproducibility, and sensitivity of DS. TwinStrand Biosciences first applied DS to establish mutation frequency (MF) in DNA samples extracted from the livers of an untreated Sprague Dawley rat, or rats treated with either 100 mg/kg/day benzo[a]pyrene (B[a]P) for ten days or 40 mg/kg/day N‐ethyl‐N‐nitrosourea (ENU) for three days. Using the measured MF in these original samples, mixtures were then constructed using the B[a]P‐ and ENU‐treated samples to create “MF standards” with target MFs 1.2‐, 1.5‐, and 2‐fold greater than the untreated control. Aliquots of these standards were distributed to seven laboratories in North America and Europe. DS libraries were prepared by each laboratory and TwinStrand. All eight laboratories met library preparation and assay performance metrics to yield high quality sequencing data with MF in the expected ‘MF standard’ range. The measured MF and mutation spectra were nearly identical across the laboratories and a 2‐fold increase in MF could readily be identified in all labs relative to the untreated controls. The results confirm the high reproducibility and sensitivity of DS for mutagenicity assessment.